Search

Presentations

EHA-MSH Hematology Tutorial

Session 1: Basic Principles of Hodgkin Lymphoma

Lecture: MJ Kersten (Not available)
Clinical Case: PL Low (Not available)
Self-assessment case: MJ Kersten (Not available)
Session 2: Histopathology and Diagnosis

Lecture: MA Piris (here)
Clinical Case: CC Liong (here)
Self-assessment case: MA Piris (here)
Session 3: Treatment of Newly Diagnosed Hodgkin Lymphoma

Lecture: A Czyż (here)
Clinical…

Selection panel and principles

Selection panel
EHA Board — Margarita Guenova
EHA Board — Jose Maria Ribera
Community and Stakeholder Committee — Darko Antic
Diversity, Equity, and Inclusion Taskforce — Mihnea-Alexandru Gaman
Education Committee — Jose Tomás Navarro Ferrando
European Affairs Committee — Julio Delgado
Patient Advocacy Committee — to be…

Sponsor and Fundraising Committee

Current committee members
Martin Dreyling, Germany (Chair (EHA Board))
Antonio Pierini, Italy (Vice Chair (non-Board member))
Igor Aurer, Croatia (Representative, SWG Committee)
Mariane de Montalembert, France (Councilor)
Konstanze Döhner, Germany (EHA Board)
Kirsten Gronbaek, Denmark (EHA Board)
Frank Leebeek, The Netherlands (Councilor)
David Rees, United Kingdom (Representative, Education…

Is TRTH for me?

Please see the eligibility criteria in the dropdown menu below.

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.